Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/20/2023 | 3821.57% | HC Wainwright & Co. | $10 → $2 | Maintains | Buy |
| 01/26/2023 | 19507.84% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 37154.9% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 21468.63% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 35194.12% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 13625.49% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/20/2023 | 3821.57% | HC Wainwright公司 | $10→$2 | 维护 | 买 |
| 2023年1月26日 | 19507.84% | HC Wainwright公司 | $19→$10 | 维护 | 买 |
| 08/16/2022 | - | Maxim集团 | 评级下调 | 购买→Hold | |
| 07/20/2021 | 37154.9% | HC Wainwright公司 | $11→$19 | 维护 | 买 |
| 2020/05/15 | 21468.63% | HC Wainwright公司 | $7→$11 | 重申 | →购买 |
| 02/19/2020 | 35194.12% | 罗斯资本 | →$18 | 开始承保 | →购买 |
| 2019年12月30日 | 13625.49% | HC Wainwright公司 | →$7 | 开始承保 | →购买 |
What is the target price for Aridis Pharmaceuticals (ARDS)?
阿里迪斯制药公司(ARDS)的目标价是多少？
The latest price target for Aridis Pharmaceuticals (OTCQB: ARDS) was reported by HC Wainwright & Co. on October 20, 2023. The analyst firm set a price target for $2.00 expecting ARDS to rise to within 12 months (a possible 3821.57% upside). 2 analyst firms have reported ratings in the last year.
2023年10月20日，HC Wainwright&Co.报道了阿里迪斯制药公司(OTCQB：ARDS)的最新目标价。这家分析公司将目标价定为2美元，预计ARDS将在12个月内升至(可能上涨3821.57%)。去年有两家分析公司公布了评级。
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
分析师对阿里迪斯制药(ARDS)的最新评级是多少？
The latest analyst rating for Aridis Pharmaceuticals (OTCQB: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals maintained their buy rating.
分析师对阿里迪斯制药公司(场外交易代码：ARDS)的最新评级是由HC Wainwright&Co.提供的，阿里迪斯制药公司维持其买入评级。
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
阿里迪斯制药公司(ARDS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on October 20, 2023 so you should expect the next rating to be made available sometime around October 20, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与阿里迪斯制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。阿里迪斯制药的上一次评级是在2023年10月20日提交的，所以你应该预计下一次评级将在2024年10月20日左右的某个时候公布。
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
分析师对阿里迪斯制药公司(ARDS)的评级正确吗？
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a maintained with a price target of $10.00 to $2.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $0.05, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的阿里迪斯制药(ARDS)评级维持不变，目标价在10.00美元至2.00美元之间。阿里迪斯制药(ARDS)目前的交易价格为0.05美元，超出了分析师的预测区间。